You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
瑞銀:首予藥明生物(2269.HK)“買入”評級 目標價120港元
格隆匯 01-06 10:42
瑞銀髮表報告,首次覆蓋研究藥明生物(2269.HK) ,予其“ 買入 ”評級,目標價120港元,預期隨着全球生物科技迅速發展,集團於2018年至2023年間的收入及純利年均複合增長率可分別達45%及48%。該行表示,預計全球生物製藥外包市場在2018年至2023年的年均複合增長為18%,而中國的增長更可達33%,主要由於生物科技行業快速增長,及因監管趨嚴和成本壓力增加,使外包服務需求強勁。
瑞銀提到,藥明生物的主要增長推動力來自全球中小型生物科技公司,在去年上半年,集團有53%的總收入來自美國市場,中國及歐洲市場的收入則分別佔35%及7%。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account